The key contribution of CD8+ T cells and IFNγ as a mechanism for increased anti‐tumor immunity upon PD‐1 blockade is well established1 and is likely to be mechanistically linked to anti‐RANKL/PD‐1 BsAb efficacy. The gene discussed is PDCD1; the disease is neoplasm.